NCT06397157 Combined Effects of Virtual Reality and Motor Imagery in Patients With Non-specific Neck Pain
| NCT ID | NCT06397157 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Cervical Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 93 participants |
| Start Date | 2023-12-10 |
| Primary Completion | 2024-06-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 93 participants in total. It began in 2023-12-10 with a primary completion date of 2024-06-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Non-specific neck pain is the most common musculoskeletal symptom which can cause limited cervical mobility, impaired functional status and stress at work. Virtual reality and motor imagery are unique technologies which have beneficial effects on the treatment of non-specific neck pain. Virtual reality is a simulated 3D environment that enables users to explore and interact with a virtual surrounding while motor imagery (MI) is a dynamic mental process of an action, without its actual motor execution. This study aims to investigate the combined effects of Virtual Reality (VR) and Motor Imagery Techniques (MI) with Routine Physical Therapy (RPT) in patients with Non-specific neck pain. This randomized clinical trial will be carried at Railway General Hospital, Rawalpindi on 93 participants meeting the inclusion criteria included in the study through probability convenience sampling technique. 3 groups of participants assigned ramdomly will receive interventions for three days a week for 6 weeks. Group A will receive virtual reality (VR) and motor imagery (MI) along with routine physical therapy for . Group B participants will receive VR along with routine physical therapy while Group C will receive MI along with routine physical therapy. Total treatment time will be 40 minutes. Outcome measure tools will be Numeric pain rating scale to measure pain, the Tampa scale of Kinesiophobia (TSK) for the measurement of kinesiophobia and Neck disability index for disability and functional status.
Eligibility Criteria
Inclusion Criteria: * Age of the patients should be 18-50 years * Both females and males are included * Patient should have a consistent pain for 3 months or more. * Patient having non-specific neck pain. Exclusion Criteria: * Specific neck pain caused by metastasis, neoplasia, infectious or inflammatory disorders, bone fractures or traumatic precedents with neck injuries (2) * Positive neurological signs or evidence of spinal compression (abnormal diffuse sensitivity, hyperreflexia, or diffuse weakness) * Cervical osteoarthritis * Spondylarthritis * Neck pain associated with vertigo (vestibular involvement) * Neck pain associated with whiplash injuries * Previous cervical surgeries (2) * Headaches before the onset of neck pain and without cervical origin * Inability to provide informed consent
Contact & Investigator
Sabiha Arshad, M phil
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT06397157 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Cervical Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06397157 currently recruiting?
Yes, NCT06397157 is actively recruiting participants. Contact the research team at iqbal.tariq@riphah.edu.pk for enrollment information.
Where is the NCT06397157 trial being conducted?
This trial is being conducted at Rawalpindi, Pakistan.
Who is sponsoring the NCT06397157 clinical trial?
NCT06397157 is sponsored by Riphah International University. The principal investigator is Sabiha Arshad, M phil at Riphah International University. The trial plans to enroll 93 participants.